DE-111 ophthalmic solution — Competitive Intelligence Brief

DE-111 ophthalmic solution (DE-111 ophthalmic solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D1 receptor agonist. Area: Ophthalmology.

phase 3 Dopamine D1 receptor agonist Dopamine D1 receptor Ophthalmology Small molecule

Target snapshot

DE-111 ophthalmic solution (DE-111 ophthalmic solution) — Santen Pharmaceutical Co., Ltd.. DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DE-111 ophthalmic solution TARGET	DE-111 ophthalmic solution	Santen Pharmaceutical Co., Ltd.	phase 3	Dopamine D1 receptor agonist	Dopamine D1 receptor
DSP-5423P Active-to-Flex	DSP-5423P Active-to-Flex	Sumitomo Pharma Co., Ltd.	phase 3	Dopamine D1 receptor partial agonist	Dopamine D1 receptor (DRD1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D1 receptor agonist class)

1. Santen Pharmaceutical Co., Ltd. · 1 drug in this class